4/9/2013

An appellate court panel refused to grant Pfizer a new trial, upholding a $142 million penalty against the drugmaker for fraudulent marketing of the epilepsy drug Neurontin. The judges also restored similar lawsuits that had been rejected by a lower court.

Full Story:
Reuters

Related Summaries